ConSynance Therapeutics Reports Positive Phase 1 Results for CSTI-500 in Prader-Willi Syndrome Patients RENSSELAER, New York, May 30, 2023 (GLOBE NEWSWIRE) -- ConSynance Therapeutics, Inc., an emerging biopharmaceutical firm focused on developing novel therapies for rare central nervous system (CNS)...